Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/22/14 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/21/14 | DEF 14A | Definitive proxy statements |
|
46 | |
| 01/17/14 | 8-K/A | Current report filing |
|
25 | |
| 01/17/14 | S-3/A | Registration statement for specified transactions by certain issuers |
|
13 | |
| 01/15/14 | 8-K | Current report filing |
|
40 | |
| 01/08/14 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
46 | |
| 01/02/14 | 8-K | Current report filing |
|
43 | |
| 12/31/13 | S-3 | Registration statement for specified transactions by certain issuers |
|
46 | |
| 12/19/13 | 8-K | Current report filing |
|
5 | |
| 12/12/13 | 8-K | Current report filing |
|
18 |
